Korean Journal of Transplantation, 2023 Background : Graft-versus-host disease (GVHD) is a rare, but potentially fatal complication of liver transplantation. One-way human leukocyte antigens (HLA) mismatch has emerged as a risk factor for GVHD.
Seung Hyuk Yim +4 more
doaj +1 more source
GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. [PDF]
, 2019 We report graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) (a composite end point of survival without grade III-IV acute GVHD [aGVHD], systemic therapy-requiring chronic GVHD [cGVHD], or relapse) and cGVHD-free relapse-free survival ...
Abdel-Azim, Hisham +53 more
core +2 more sources
Pathologic analysis of liver transplantation for primary biliary cirrhosis [PDF]
, 1988 A retrospective histopathologic review of all pathologic specimens from 394 adult liver transplant patients was undertaken with clinical correlation to determine if primary biliary cirrhosis has affected the posttrans‐plant course compared to all other ...
Ballardini +25 more
core +1 more source
Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. [PDF]
, 2017 Purpose T-cell-replete HLA-haploidentical donor hematopoietic transplantation using post-transplant cyclophosphamide was originally described using bone marrow (BM).
Al Malki, Monzr M +23 more
core +2 more sources
Treatments and supportive therapies for oral manifestations of chronic graft-versus-host disease
Acta Scientiarum. Health Sciences, 2016 The aim of this study was to conduct a systematic review of treatments and therapies for oral manifestations of chronic graft-versus-host disease, aiming at improving patients’ quality of life and mainly the reduction of mortality caused by graft-versus-
Rafaella Gabriel Maiolino +5 more
doaj +1 more source
Haematologica, 2015 Effective pharmacological strategies employed in allogeneic hematopoietic cell transplantation should prevent serious chronic graft-versus-host disease and facilitate donor-recipient immune tolerance.
Joseph Pidala +15 more
doaj +1 more source
Frontiers in Immunology, 2020 Graft-versus-host disease (GvHD) remains the second leading cause of death in allogeneic hematopoietic stem cell transplantation recipients, highlighting the need for improved preventative strategies.
Megan S. Molina +14 more
doaj +1 more source
Immunomagnetic t-lymphocyte depletion (ITLD) of rat bone marrow using OX-19 monoclonal antibody [PDF]
, 1989 Graft versus host disease (GVHD) may be abrogated and host survival prolonged by in vitro depletion of T lymphocytes from bone marrow (BM) prior to allotransplantation. Using a mouse anti-rat pan T-lymphocyte monoclonal antibody (0×19) bound to monosized,
A. Pascualone +30 more
core +1 more source
Hematology, Transfusion and Cell Therapy, 2018 Background: Hematopoietic stem cell transplantation is a curative treatment for many patients with hematological disorders. Donor–recipient genetic disparity, especially involving the human leukocyte antigen system is a critical factor for transplant ...
Alessandra Paz +12 more
doaj +1 more source
Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation [PDF]
, 2017 BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for patients with acute myeloid leukemia (AML). However, post-HCT relapse and regimen-related toxicity remain significant barriers to long-term survival.
Al Mumma +41 more
core +1 more source